The company provides student recruitment outsourcing, a software-as-a-service (SaaS) platform for academic administration, and online program management services for higher education institutions in India.
The company lacks a durable moat as evidenced by deeply negative average net margins and negligible returns on capital. While they claim switching costs via their SaaS platform, the financial results show a business that is essentially a small-scale service provider heavily dependent on related-party institutions for revenue.
Capital allocation has been poor, characterized by a history of losses that have wiped out net worth. Recent activity includes a rights issue at par value to fund operations and the conversion of related-party loans into equity to clean up a distressed balance sheet.
The company's survival was predicated on a life-support system of related-party transactions that eventually collapsed. As the Padode family entities faced their own liquidity constraints, the primary revenue stream evaporated, revealing a core business that never possessed independent unit profitability. The rights issue and debt-to-equity conversions proved to be mere accounting maneuvers that delayed but could not prevent a total wipeout of shareholder equity as chronic losses continued to erode the capital base.
RichFakir rates DSJ Keep Learning Ltd's business quality as poor — 31/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, DSJ Keep Learning Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on DSJ Keep Learning Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of DSJ Keep Learning Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →